|
18 Sep 2025 |
Cipla
|
Consensus Share Price Target
|
1559.60 |
1676.69 |
- |
7.51 |
buy
|
|
|
|
|
27 Jan 2023
|
Cipla
|
ICICI Securities Limited
|
1559.60
|
1082.00
|
1035.25
(50.65%)
|
Target met |
Hold
|
|
|
Cipla’s Q3FY23 performance was largely in line with our estimates. Revenue grew 6% YoY to Rs58.1bn (I-Sec: Rs.58.8bn) driven by a strong uptick in US revenue (US$195mn, +8.9% QoQ), which partially benefitted from continued traction in Revlimid and a strong seasonal quarter of its key products.
|
|
27 Jan 2023
|
Cipla
|
SMC online
|
1559.60
|
|
1047.25
(48.92%)
|
|
Results Update
|
|
|
|
|
27 Jan 2023
|
Cipla
|
Axis Direct
|
1559.60
|
1300.00
|
1047.25
(48.92%)
|
Target met |
Buy
|
|
|
We recommend a BUY rating on the stock with a TP of Rs 1,300/share.
|
|
27 Jan 2023
|
Cipla
|
ICICI Direct
|
1559.60
|
1290.00
|
1047.25
(48.92%)
|
Target met |
Buy
|
|
|
|
|
26 Jan 2023
|
Cipla
|
BOB Capital Markets Ltd.
|
1559.60
|
1250.00
|
1035.25
(50.65%)
|
Target met |
Buy
|
|
|
Q3 revenue grew 6% YoY to Rs 58bn (11% ex-Covid sales last year) driven by US business and despite a sharp decline in SAGA
|
|
15 Dec 2022
|
Cipla
|
Motilal Oswal
|
1559.60
|
1180.00
|
1089.40
(43.16%)
|
Target met |
Neutral
|
|
|
|
|
10 Nov 2022
|
Cipla
|
Geojit BNP Paribas
|
1559.60
|
1230.00
|
1121.40
(39.08%)
|
Target met |
Hold
|
|
|
|
|
09 Nov 2022
|
Cipla
|
SMC online
|
1559.60
|
|
1122.30
(38.96%)
|
|
Results Update
|
|
|
|
|
07 Nov 2022
|
Cipla
|
ICICI Direct
|
1559.60
|
1350.00
|
1130.90
(37.91%)
|
|
Buy
|
|
|
|
|
07 Nov 2022
|
Cipla
|
ICICI Securities Limited
|
1559.60
|
1091.00
|
1146.10
(36.08%)
|
Target met |
Hold
|
|
|
Cipla’s Q2FY23 performance was ahead of our estimates on reported front but adjusting for Revlimid sales it was broadly in-line.
|